InvestorsHub Logo
Followers 30
Posts 2777
Boards Moderated 3
Alias Born 10/24/2015

Re: flipper44 post# 227889

Saturday, 05/18/2019 12:32:17 PM

Saturday, May 18, 2019 12:32:17 PM

Post# of 687234
Prior to Yescara, R/R DLBCL patients had a mOS of just over 6 months [1]. At two years, after a single infusion, just over half of this same patient population are still alive. The mOS has not yet been reached [2].

GILD/KITE is working on bi- and trispecific 3rd, and 4th Gen constructs along with much more to improve the safety and efficacy.


Refs:
1 http://www.bloodjournal.org/content/early/2017/08/02/blood-2017-03-769620
2 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30864-7/fulltext
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News